The National Development and Reform Commission announced that it will focus on supporting these medi



According to the latest news, the National Development and Reform Commission has formulated and issued the “Three-Year Action Plan for Enhancing the Core Competitiveness of Manufacturing Industry (2018-2020)”.

The action plan proposes that by the end of the 'Thirteenth Five-Year Plan', key areas of manufacturing industry must break through a number of major key technologies to achieve industrialization, form a group of leading enterprises with international influence, create a group of well-known brands made in China, and create a Approved internationally recognized Chinese standards, the manufacturing innovation capability has improved significantly, product quality has been greatly improved, and comprehensive quality has been significantly enhanced.

The Action Plan has put together nine key manufacturing areas that focus on enhancing core competencies, and “the industrialization of key technologies for high-end medical devices and drugs”.

In this area, the key tasks of industrialization are:

1. Accelerate the industrialization and application of high-end medical devices.

Focus on supporting the industrialization of innovative medical devices such as PET-MRI, ultrasound endoscopy, surgical robots, and full laboratory automated inspection and analysis line (TLA).

Supports high-performance imaging equipment such as PET-CT, CT, MRI, high-energy linear accelerators and image-guided radiotherapy devices, high-throughput gene sequencers, chemiluminescence immunoassays, and new molecular diagnostic instruments. Diagnostic products, new implant intervention products such as fully degradable coronary stents, nerve stimulators, tissue-induced regeneration and repair materials, high-end intelligent rehabilitation aids, high-precision real-time inspection systems (POCT) and other product upgrades and quality performance improvements.

2. Promote the industrialization and application of high-end drugs.

Targeting the treatment of major diseases such as tumors, cardiovascular and cerebrovascular diseases, diabetes, immune system, viruses and drug-resistant infections, we promote the development and industrialization of innovative drugs with targeted, highly selective and new mechanisms of action.

Support the development and industrialization of the first chemical generic drugs and biosimilar drugs with long market potential and high clinical value, and support the upgrading of product industry through the evaluation of the quality and efficacy of generic drugs.

Supporting 1-2 new drugs (new and improved new drugs), new drugs (including ethnic medicines) and new classics, and the first in China, which have obtained new drug certificates or have been declared for new drug production since 2015. The industrialization of biopharmaceuticals listed on the market.

3. Strengthen the construction of specialized technical service platforms.

Support the construction of medical equipment, pharmaceutical specialization consulting, research and development, production and application demonstration service platform, and provide public services such as key technology development, standard formulation, quality testing and evaluation, clinical research, application demonstration, etc. to promote comprehensive transformation and upgrading of the industry and promote Improve product quality and performance, improve the division of labor and production intensification in the pharmaceutical industry.